Weight-loss drug developer Metsera raises $275 million in US IPO
(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...
Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs
A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...
Pimco’s stake in Venture Global now worth $7B, WSJ says
Pimco, one of the world’s largest bond managers, owns 354 million Class A shares of Venture Global (VG), the natural-gas exporter that went ...
Lake Charles American Press8h
Business Briefs: Venture Global goes public
Shares in Venture Global are expected to make their debut on the New York Stock Exchange after the company raised $1.75 ...